文献速递膀胱癌与上尿路尿路上皮癌

膀胱效用症状量表:一种新的膀胱癌患者报告结局工具

The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer.
PubMed 文献 · J Urol · 2018-03-09

本研究分三部分开发并验证膀胱效用症状量表(BUSS),用于评估膀胱癌患者整体健康相关生活质量。BUSS与FACT-Bl全量表相关系数rs=0.82(p<0.0001),重测信度ICC=0.79,完成率94%,在合并症和晚期疾病患者中得分更低。BUSS是适用于所有膀胱癌患者(不论治疗方式或疾病分期)的可靠且有效的患者报告结局工具。

要点

  • BUSS与FACT-Bl全量表高度相关(rs=0.82,p<0.0001),效度良好。
  • 重测信度ICC=0.79,完成率94%,提示可靠且易懂。
  • 合并症和晚期疾病患者BUSS得分更低,可区分不同健康状况。

核心结论

  • BUSS是适用于所有膀胱癌患者(不论治疗方式或疾病分期)的可靠且有效的健康相关生活质量患者报告结局工具。

研究设计与样本

  • 前瞻性问卷开发研究分三部分:研究1由专家基于患者焦点小组构建概念框架创建BUSS问题;研究2让接受手术、放疗和化疗的膀胱癌患者在基线和4周完成BUSS及5种健康相关生活质量工具以评估效度和重测信度;研究3在578例患者中在线和门诊施测BUSS探索外部效度。

主要发现

  • BUSS全量表与FACT-Bl(癌症治疗功能评估-膀胱)高度相关(rs=0.82,p<0.0001)。
  • BUSS子量表与EQ-5D™-3L(欧洲五维健康量表-3水平)呈中到高度相关,如情绪健康rs=0.69(p<0.0001)。
  • 合并症患者和晚期疾病患者BUSS得分更低。
  • 认知访谈和94%完成率提示良好可理解性。
  • 重测信度优秀(ICC=0.79)。

关键数值与推荐

  • BUSS与FACT-Bl全量表相关系数rs=0.82(p<0.0001)。
  • BUSS情绪健康子量表与EQ-5D™-3L相关系数rs=0.69(p<0.0001)。
  • 重测信度ICC=0.79,完成率94%。

临床怎么用

  • BUSS可用于膀胱癌患者整体健康相关生活质量的标准化评估,不受治疗方式或疾病分期限制,便于临床决策和研究中比较不同治疗模式的生活质量影响。

局限性

  • 许多患者从诊断到研究入组时间较长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Health related quality of life is important in bladder cancer care and clinical decision making because patients must choose between diverse treatment modalities with unique morbidities. A patient reported outcome measure of overall health related quality of life for bladder cancer regardless of disease severity and treatment could benefit clinical care and research. MATERIALS AND METHODS: Prospective questionnaire development was completed in 3 parts. In study 1 the BUSS (Bladder Utility Symptom Scale) questions were created by experts using a conceptual framework of bladder cancer health related quality of life generated through patient focus groups. In study 2 patients with bladder cancer, including those treated with surgery, radiation and chemotherapy, completed the BUSS and 5 health related quality of life instruments at baseline and 4 weeks to assess validity and test-retest reliability. External validity was then explored in study 3 by administering the BUSS to 578 patients online and at clinics. Construct validity was assessed by whole and subscale Spearman rank correlations, and by comparisons of BUSS scores across known groups. RESULTS: The BUSS had high whole scale correlation with the FACT-Bl (Functional Assessment of Cancer Therapy-Bladder) (rs = 0.82, p <0.0001) and substantial to high subscale correlations with the EQ-5D™-3L (EuroQol 5 Dimensions Questionnaire-3 Levels) (eg emotional well-being rs = 0.69, p <0.0001). BUSS scores were lower in patients with comorbidity and advanced disease. Cognitive debriefing and the 94% completion rate suggested good comprehensibility. There was excellent test-retest reliability (ICC = 0.79). Limitations included an extended time from diagnosis in many patients. CONCLUSIONS: The BUSS is a reliable and valid patient reported outcome instrument for health related quality of life in all patients with bladder cancer regardless of the treatment received or the stage of disease.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Perlis N, Krahn MD, Boehme KE, et al. The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. J Urol. 2018. PMID: 29530786. doi:10.1016/j.juro.2018.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。